Related Experiment Video
Updated: Jun 14, 2025
00:04
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.6K
Futility Monitoring in Clinical Trials
Ana M Ortega-Villa1, Megan C Grieco1,2, Kevin Rubenstein3
1Office of Biostatistics Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
Statistics in Medicine
|June 11, 2025
Summary
This tutorial explores clinical trial futility, offering methods to determine when to stop a trial based on early negative trends. It provides tools to distinguish optimism from denial in phase III clinical trials.
Area of Science:
- Clinical trial methodology
- Biostatistics
- Drug development
Background:
- Phase III clinical trials often begin with optimism based on encouraging Phase II results.
- Early negative trends in Phase III trials raise questions about potential futility.
- Deciding when a trial is futile is critical to resource allocation and patient safety.
Purpose of the Study:
- To review concepts and tools for evaluating clinical trial futility.
- To provide guidance on distinguishing between optimism and denial in ongoing trials.
- To define and assess the meaning of clinical trial futility.
Main Methods:
- Review of statistical concepts for futility assessment.
- Explanation of conditional power and predictive power.
- Discussion of reverse conditional power and predicted interval plots.
- Introduction to revised unconditional power and beta spending functions.
Main Results:
- Futility assessment requires careful statistical evaluation, not just optimism.
- Various statistical tools can quantify the probability of trial success given early data.
- Understanding these tools helps in making informed decisions about trial continuation or termination.
Conclusions:
- Early identification of futility in clinical trials is crucial.
- Statistical methods provide objective measures to guide decisions.
- Appropriate use of futility analysis optimizes drug development and patient outcomes.
Related Concept Videos
01:16Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
01:24Kaplan-Meier Approach
111
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
111
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
01:09Censoring Survival Data
72
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
72
01:11Renal Failure: Dose Adjustments
68
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
68
01:17Factors Affecting Renal Clearance: Renal Impairment
62
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
62